Home ›
Entities
› academia
› Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews
Research article (Health Research Policy and Systems, 2017) · cited 12× · AI/ML
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews
Summary
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews is a scholarly article[1].
Key Facts
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews. Retrieved May 24, 2026, from https://4ort.xyz/entity/why-european-and-united-states-drug-regulators-are-not-speaking-with-one-voice-on-anti-influenza-drugs-regulatory-review
MLA“Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/why-european-and-united-states-drug-regulators-are-not-speaking-with-one-voice-on-anti-influenza-drugs-regulatory-review.
BibTeX@misc{4ortxyz_why-european-and-united-states-drug-regulators-are-not-speaking-with-one-voice-on-anti-influenza-drugs-regulatory-review_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews}}, year = {2026}, url = {https://4ort.xyz/entity/why-european-and-united-states-drug-regulators-are-not-speaking-with-one-voice-on-anti-influenza-drugs-regulatory-review}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews — https://4ort.xyz/entity/why-european-and-united-states-drug-regulators-are-not-speaking-with-one-voice-on-anti-influenza-drugs-regulatory-review (retrieved 2026-05-24)
